TAIHO PHARMACEUTICAL CO., LTD.

ACTIVE

1-27, KANDANISHIKICHO, Chiyoda-Ku, 东京都, Japanwww.taiho.co.jpSubsidiary1,001–5,000 employeesEstablished: 1963-01-01

Also known as:

taiho pharmaceutical co., ltd. kitajima plant

taiho pharmaceutical co., ltd. saitama plant

Part of OTSUKA HOLDINGS CO., LTD.

Clinical Trials

285

12 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1963

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

30.2%

Phase 2

28.1%

Phase 1

23.5%

Unknown

3.5%

Not Applicable

2.8%

Trial Status Distribution

Active, not recruiting

3.9%

Completed

120

42.1%

Not yet recruiting

0.3%

Recruiting

6.3%

Suspended

0.7%

Terminated

1.1%

Clinical Trials

Trials sponsored by this organization (285)

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

Phase 3

Recruiting

interventional

Jun 2026784 participants

Research study on the treatment patterns of gastrointestinal stromal tumor (GIST) using the claims database

Unknown

Completed

observational

Apr 20241,847 participants

Web Questionnaire Survey Study on adverse effects of trifluridine/tipiracil for patients and doctors.

Unknown

Not yet recruiting

observational

Jan 2024250 participants

Zimberelimab and domvanalimab in combination with chemotherapy versus pembrolizumab with chemotherapy in patients with untreated metastatic non-small cell lung cancer (STAR-121)

Recruiting

interventional

Jan 202450 participants

Randomized Phase 3 Trial of Domvanalimab + Zimberelimab + Chemotherapy vs. Nivolumab + Chemotherapy in Adults with Advanced Upper Gastrointestinal Tract Adenocarcinoma (STAR-221)

Active, not recruiting

interventional

Jun 2023970 participants

A Drug-Drug Interaction Study of TAS5315 with CYP3A inhibitor in Healthy Adult Subjects

Completed

interventional

May 202320 participants

A clinical study of non-invasive diagnostic criteria for detrusor underactivity

Active, not recruiting

observational

May 2023186 participants

A Thorough QT/QTc Study of TAS5315 in Healthy Adult Subjects

Completed

interventional

Mar 202348 participants

Page 1 of 36

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

Approvals

FDA

Food and Drug Administration

Approvals

PHILIPPINES

Philippines FDA

Approvals

NPRA

National Pharmaceutical Regulatory Agency

Approvals

Recent Approvals

Lonsurf Film-coated Tablet 15 mg/6.14 mg (Trifluridine/Tipiracil)

NPRA

2025-11-28

Lonsurf Film-coated Tablet 20 mg/8.19 mg (Trifluridine/Tipiracil)

Trifluridine and Tipiracil Hydrochloride Tablets

NMPA

2024-08-06

Trifluridine and Tipiracil Hydrochloride Tablets

News

No news articles found

Back to Organizations